Efficacy of a Bioresorbable Matrix in Healing Complex Chronic Wounds

An Open-Label Prospective Pilot Study

Sarah W. Manning, MD; David A. Humphrey, MD; William R. Shillinglaw, DO; Eric Crawford; Gaurav Pranami, PhD; Ankit Agarwal, PhD; Michael J. Schurr, MD


Wounds. 2020;32(11):309-318. 

In This Article


This clinical study evaluated the effectiveness of a novel bioresorbable matrix as an intervention to stalled chronic wounds that were stagnant or deteriorating for a median of 39 weeks. The wounds were not responding to prior treatment plans with antibiotics and traditional antimicrobial dressings, and were suspected of persistent microbial colonization prior to study inclusion. When the matrix was included in the treatment plan, 72% of the wounds had shown improved healing within 3 weeks, while 91% of the wounds either healed completely (ie, fully reepithelialized) or improved significantly within 12 weeks, with an average wound area reduction of 73%. Patients tolerated the matrix with no reports of discomfort, pain, or AEs. The study outcomes concluded that the application of the matrix directly to the wound surface was safe and well tolerated as well as facilitated improvements in healing of the majority of the stagnant or deteriorating complex, chronic wounds. The micrometer-thick form factor of the matrix with ionic and metallic silver appeared to be an effective alternative to traditional antimicrobial dressings in the management of complex, nonhealing wounds. The results emphasize that this bioresorbable matrix technology may play a significant role in the effective management of hard-to-heal wounds that are unresponsive to standard of care and could be an effective primary antimicrobial wound dressing in protocols of care for complex wounds at risk of infection.